Study S001119

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01907854
Acronym: LIRA-SWITCH™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 407
Start: 2013-12-02
Primary completion: 2015-06-15
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:sitagliptin; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2012-004931-22; OTHER:U1111-1136-2073; REGISTRY:CTRI/2014/05/004623

Registered primary outcomes

Change in HbA1c (Glycosylated Haemoglobin) [From baseline to week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025720	Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Bailey TS, Diabetes, obesity & metabolism	2016	Randomized trial	PMID 27381275 DOI	registry reference RESULT:27381275